BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35094841)

  • 1. [New drug approval: Sacituzumab govitecan in third line in advanced or metastatic triple-negative breast cancer].
    Kabirian R; Da Silva A
    Bull Cancer; 2022 Mar; 109(3):249-250. PubMed ID: 35094841
    [No Abstract]   [Full Text] [Related]  

  • 2. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
    Wahby S; Fashoyin-Aje L; Osgood CL; Cheng J; Fiero MH; Zhang L; Tang S; Hamed SS; Song P; Charlab R; Dorff SE; Ricks TK; Barnett-Ringgold K; Dinin J; Goldberg KB; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1850-1854. PubMed ID: 33168656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
    N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
    N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A closer look at sacituzumab govitecan-hziy.
    Bardia A
    Clin Adv Hematol Oncol; 2020 Nov; 18(11):715-717. PubMed ID: 33406063
    [No Abstract]   [Full Text] [Related]  

  • 7. Sacituzumab govitecan activity in advanced breast cancer.
    Burki TK
    Lancet Oncol; 2017 May; 18(5):e246. PubMed ID: 28343977
    [No Abstract]   [Full Text] [Related]  

  • 8. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer.
    Bardia A
    Clin Adv Hematol Oncol; 2021 Nov; 19(11):723-725. PubMed ID: 34807017
    [No Abstract]   [Full Text] [Related]  

  • 10. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 12. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
    Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
    Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacituzumab govitecan-hziy for triple-negative breast cancer.
    Stirrups R
    Lancet Oncol; 2019 Apr; 20(4):e194. PubMed ID: 30827748
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of sacituzumab govitecan in solid tumors.
    Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
    J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):e25-e27. PubMed ID: 33757114
    [No Abstract]   [Full Text] [Related]  

  • 16. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
    Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
    Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 18. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
    Baek G; Jung L; Duong A; Gralow J
    J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histologic subtypes in chemotherapy vs. sacituzumab sovitecan groups might affect progression-free and overall survival in metastatic triple-negative breast cancer.
    Altundag K
    J BUON; 2021; 26(3):1174-1175. PubMed ID: 34268994
    [No Abstract]   [Full Text] [Related]  

  • 20. An ADC for Triple-Negative Breast Cancer.
    Cancer Discov; 2016 Jan; 6(1):OF8. PubMed ID: 26577300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.